Search clinical trials for: BIBF 1120 ES

Total 1238 results

Boehringer Ingelheim

Completed

Efficacy and Safety of Oral Treatment With BIBF 1120 ES in Advanced Non-small-cell Lung Cancer

Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim

Completed

A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer

Prostatic Neoplasms

United Kingdom
Boehringer Ingelheim

Completed

An Dose Escalation Study of BIBF 1120 Administered in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent

Recurrent Pleural Malignant Mesothelioma | Stage IV Pleural Mesothelioma

United States
Boehringer Ingelheim

Terminated

BIBF 1120 in Combination With Pemetrexed in Advanced Non Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

Japan
Boehringer Ingelheim

Completed

Metabolism and Pharmacokinetics of [14C]-BIBF 1120 in Healthy Male Volunteers

Healthy
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Squamous Cell Carcinoma | Malignant Uterine Corpus Mixed Epithelial and Mesenchymal Neoplasm

United States
Boehringer Ingelheim

Completed

BIBF 1120 + Docetaxel (Japan) in Patients With Advanced Non-small-cell Lung Cancer, Phase I

Carcinoma, Non-Small-Cell Lung

Japan
Boehringer Ingelheim

Completed

Safety and Relative Bioavailability of BIBF 1120 Soft Gelatine Capsules Charge 1, BIBF 1120 Soft Gelatine Capsules Charge 2 and BIBF 1120 Drinking Solution in Healthy Male Volunteers

Healthy
Roswell Park Cancer Institute
National Cancer Institute (NCI); Boehringer Ingelheim

Completed

Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens

Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Squamous Cell Lung Cancer | Stage III Non-small Cell Lung Cancer

United States
Boehringer Ingelheim

Completed

Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.

Neoplasms

France
Roswell Park Cancer Institute
National Cancer Institute (NCI); Boehringer Ingelheim; National Comprehensive...

Completed

Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer

Recurrent Colon Carcinoma | Recurrent Rectal Carcinoma | Rectal Adenocarcinoma | Colon Adenocarcinoma | Stage IVA Colon Cancer | Stage IVA Rectal Cancer | Stage IVB Colon Cancer | Stage IVB Rectal Cancer

United States
Boehringer Ingelheim

Completed

Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid Tumors

Neoplasms

United States
Boehringer Ingelheim

Completed

Safety And Efficacy of BIBF 1120 in Idiopathic Pulmonary Fibrosis

Pulmonary Fibrosis

Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czech Republic, France, Germany, Greece, Hungary, Ireland, Italy, Korea, Republic of, Mexico, Netherlands, Portugal, Russian Federation, South Africa, Spain, Taiwan and more
Roswell Park Cancer Institute
National Comprehensive Cancer Network

Completed

Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors

Carcinoid Tumor | Neuroendocrine Neoplasm | Metastatic Carcinoid Tumor

United States
Boehringer Ingelheim

Completed

A Phase II Trial of Weekly Alternating Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Advanced Colorectal Cancer

Colorectal Neoplasms

France
Boehringer Ingelheim

Completed

A Study With BIBF 1120 in Patients With Hormone Refractory Prostate Cancer

Prostatic Neoplasms
University College, London
Boehringer Ingelheim

Completed

Low Dose Cyclophosphamide +/-- Nintedanib in Advanced Ovarian Cancer (METRO-BIBF)

Ovarian Cancer | Fallopian Tube Cancer

United Kingdom
Northwestern University
National Cancer Institute (NCI); Boehringer Ingelheim; Robert H. Lurie Cancer...

Active, not recruiting

Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A | Fibroblast Growth Factor Basic Form Measurement | FLT3 Internal Tandem Duplication

United States
Boehringer Ingelheim

Completed

Safety and Tolerability Study of BIBF 1120 as Intravenous Infusion and Absolute Bioavailability of BIBF 1120 as Soft Gelatine Capsule in Healthy Subjects

Healthy
Boehringer Ingelheim

Terminated

Dose Escalation Study of BIBF 1120 in Combination With Carboplatin and PLD in Relapsed Ovarian Cancer (OC)

Ovarian Neoplasms

Japan
University of Cologne
Boehringer Ingelheim

Completed

BIBF 1120 and RAD001 in Solid Tumors - Phase I (BARIS)

Solid Tumors

Germany
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Terminated

Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy

Lung Non-Squamous Non-Small Cell Carcinoma | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV... and other conditions

United States
Boehringer Ingelheim

Completed

BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer

Ovarian Neoplasms | Peritoneal Neoplasms

Spain
Boehringer Ingelheim

Completed

Pharmacokinetics/Bioavailability of BIBF 1120 Administered to Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Roll Over Study From 1199.30 BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF)

Pulmonary Fibrosis

Spain, Belgium, Canada, Germany, China, United Kingdom, Australia, Ireland, Italy, Mexico, Netherlands, Portugal, Argentina, France, Russian Federation, Greece, Czechia, Brazil, Bulgaria, Chile, Hungary
Boehringer Ingelheim

Completed

Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients

Pulmonary Fibrosis

United States, Australia, Belgium, China, Czech Republic, France, Germany, India, Ireland, Israel, Italy, Japan, United Kingdom
JI-YOUN HAN
National Cancer Center, Korea

Completed

BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer

Small Cell Lung Cancer | Small Cell Lung Cancer Recurrent

Korea, Republic of
Boehringer Ingelheim

Completed

A Phase I/II Open Label Extension Study of BIBF 1120 Administered Orally Once or Twice Daily to Establish Safety, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and Clinical Benefit From Previous Therapy With BIBF 1120

Neoplasms

France, Germany
Boehringer Ingelheim

Completed

A Dose-escalation Study of BIBF 1120 in Japanese Patients With Advanced Solid Tumours

Tumors
Boehringer Ingelheim

Completed

To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours

Malignant Solid Tumour

Germany
Patrick Y. Wen, MD
Massachusetts General Hospital; Boehringer Ingelheim; The Cleveland Clinic; Wake... and other collaborators

Completed

BIBF 1120 for Recurrent High-Grade Gliomas

Glioblastoma | Gliosarcoma | Anaplastic Oligoastrocytoma | Anaplastic Astrocytoma | Anaplastic Oligodendroglioma

United States
Prof. Dr. Wolfgang Wick

Terminated

NOA-12: BIBF1120 and R-RT in Glioblastoma

Glioblastoma Multiforme

Germany
Boehringer Ingelheim

Completed

Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors

Neoplasms

Italy
Boehringer Ingelheim

Completed

An Dose Escalation Study of Treatment With BIBF 1120 in Patients With Advanced Solid Tumours

Tumors
Washington University School of Medicine
National Comprehensive Cancer Network

Active, not recruiting

Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung | Non-Small Cell Lung Cancer | Nonsmall Cell Lung Cancer

United States
AA Secord
Boehringer Ingelheim

Completed

BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
Boehringer Ingelheim

Completed

Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Carcinoma, Hepatocellular

Austria, France, Germany, Hungary, Netherlands, Poland, Romania, United Kingdom
Boehringer Ingelheim

Completed

Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II

Pulmonary Fibrosis

United States, Canada, Chile, China, Finland, France, Germany, Greece, India, Japan, Korea, Republic of, Mexico, Netherlands, Portugal, Russian Federation, Spain, Turkey
Boehringer Ingelheim

Completed

Oral Treatment With BIBF 1120 Together With Docetaxel and Prednisone in Patients With Hormone Refractory Prostate Cancer

Prostatic Neoplasms
Temple University
Boehringer Ingelheim

Terminated

Continuation of Nintedanib After Single Lung Transplantation in IPF Subjects

Idiopathic Pulmonary Fibrosis | Lung Transplant; Complications

United States
Boehringer Ingelheim

Completed

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

United States, Spain, Korea, Republic of, Belgium, Australia, United Kingdom, Canada, China, Germany, Japan, Turkey, France, Ireland, Italy, Israel, Netherlands, Portugal, Greece, India, Czechia, Chile, Finland, Mexico, Russian Federation
Boehringer Ingelheim

Completed

A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients

Carcinoma, Hepatocellular

Korea, Republic of, Taiwan
Qian Chu
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma (CAPSTONE)

Sarcomatoid Carcinoma of Lung

China
Boehringer Ingelheim

Completed

A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology.

Carcinoma, Non-Small-Cell Lung

Italy, Netherlands, Spain, United Kingdom
M.D. Anderson Cancer Center
Boehringer Ingelheim

Terminated

Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC)

Breast Cancer

United States
Swiss Paraplegic Centre Nottwil

Completed

Prevention of Orthostatic Hypotension With Electric Stimulation in Persons With Acute SCI

Orthostatic Hypotension | Spinal Cord Injury

Switzerland
Martin-Luther-Universität Halle-Wittenberg
GALMED GmbH

Completed

TRICC-C (AIO-KRK-0111): BIBF 1120 Versus Placebo in Patients Receiving Oxaliplatin Plus Fluorouracil and Leucovorin (mFOLFOX6) for Advanced, Chemorefractory Metastatic Colorectal Cancer (mCRC) (AIO-KRK-0111)

Colorectal Cancer

Germany
Boehringer Ingelheim

Completed

Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)

Colorectal Neoplasms

United States, Argentina, Australia, Austria, Belgium, Canada, Czechia, Denmark, France, Germany, Hong Kong, Israel, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Poland, Portugal, Russian Federation, Spain, Sweden, Taiwan, T... and more
Tianjin Medical University Cancer Institute and...

Not yet recruiting

An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 Antibody

Esophageal Squamous Cell Carcinoma | Progression to PD-1 Antibody

China

Search clinical trials for: BIBF 1120 ES

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations